US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cardiovascular

20.00

0.0000

Volume:- -

Turnover:- -

Market Cap:843.96M

PE:-20.84

High:20.00

Open:20.00

Low:20.00

Close:20.00

52wk High:23.47

52wk Low:12.26

Shares:42.20M

Float Shares:40.69M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.9598

EPS(LYR):-0.9415

ROE:-15.18%

ROA:-7.56%

PB:3.53

PE(LYR):-21.24

Loading ...

Overview Company News Filings

AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer in Cardiovascular Treatment

Kiniksa Pharmaceuticals Highlights Cardiovascular Focus and Growth

Lexicon Pharmaceuticals’ Sotagliflozin Shows Promising Cardiovascular Benefits, Earning Buy Rating

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Positive Outlook for Alnylam Pharma Amid Promising Cardiovascular Drug Developments and Strategic Partnerships

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

AstraZeneca’s PRECEDE Study: Exploring COPD in Cardiovascular Patients

Merck (MRK) Unveils New Cardiovascular Research Data at ESC 2025 Congress

Simply Wall St.

AstraZeneca’s AZD4144: A Promising Study in Cardiovascular and Kidney Disease

Tourmaline Bio: Strong Financial Position and Promising Cardiovascular Treatment Pipeline Justify Buy Rating

Amgen’s Promising Cardiovascular Study: A Potential Game-Changer?

AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer in Cardiovascular Health

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Tempus AI (TEM) Gains FDA Clearance for New Cardiovascular Risk Detection Software

Simply Wall St.

J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk

Avricore Health Expands HealthTab™ Platform in NHS Cardiovascular Initiative

CRISPR Therapeutics (NasdaqGM:CRSP) Advances Cardiovascular Programs With Promising Trial Results

Simply Wall St.

CRISPR Therapeutics Advances Phase 1 Trials for Cardiovascular Disease Programs

MT Newswires Live

Novo Nordisk’s ZEUS Study: A Potential Game Changer in Cardiovascular Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSII/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSII","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSII\",,,,,undefined,":{"symbol":"CSII","market":"US","secType":"STK","nameCN":"Cardiovascular","latestPrice":20,"timestamp":1688155200000,"preClose":20,"halted":0,"volume":0,"delay":0,"floatShares":40687277,"shares":42198048,"eps":-0.959831,"marketStatus":"Not Yet Opened","change":0,"latestTime":"06-30 16:00:00 EDT","open":20,"high":20,"low":20,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.959831,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1757059200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1151467200000,"exchange":"NASDAQ","adjPreClose":20,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSII\",,,,,undefined,":{"symbol":"CSII","floatShares":40687277,"roa":"-7.56%","roe":"-15.18%","lyrEps":-0.941454,"shares":42198048,"dividePrice":0,"high":20,"amplitude":0,"preClose":20,"low":20,"week52Low":12.255,"pbRate":"3.53","psRate":"3.52","week52High":23.47,"institutionHeld":0.4085,"latestPrice":20,"eps":-0.959831,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.959831,"open":20,"prevYearClose":13.62},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSII\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-04-28","symbol":"CSII","reason":null,"defaultRemindTime":1682688600000,"announcedDate":"2023-04-27","type":"delisting","dateTimestamp":1682654400000},{"date":"2023-02-09","symbol":"CSII","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2022/12","expectedEps":-0.15,"defaultRemindTime":1675933200000,"name":null,"time":"Pre-Market","dateTimestamp":1675918800000,"actualEps":null},{"market":"US","date":"2022-08-02","symbol":"CSII","fiscalQuarterEnding":"2022/06","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1659412800000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2022-05-04","symbol":"CSII","fiscalQuarterEnding":"2022/03","expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1651636800000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2021-11-09","symbol":"CSII","fiscalQuarterEnding":"2021/09","expectedEps":-0.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1636434000000,"reportTimeType":"pre","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSII\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSII\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.6667,"sell":0.3333,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":6,"updateTime":1676001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSII\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSII","date":"2023-04-26","current":-22.276361,"percent":0.602228,"low":-7142.134596,"twenty":-150.263532,"median":-47.492643,"eighty":648.895851,"high":1513.025574,"avg":-244.968737,"sd":1483.721277,"marketCap":843538979},"quantilePoints":[{"date":"2020-09-11","current":-49.651896,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1352319039},{"date":"2020-09-18","current":-52.200761,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1421739934},{"date":"2020-09-25","current":-53.089223,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1445938075},{"date":"2020-10-02","current":-55.251187,"twenty":-223.145513,"median":-18.735077,"eighty":649.10488,"marketCap":1504821337},{"date":"2020-10-09","current":-56.017337,"twenty":-223.145513,"median":-18.776934,"eighty":649.10488,"marketCap":1525688193},{"date":"2020-10-16","current":-56.842422,"twenty":-223.145513,"median":-18.865697,"eighty":649.10488,"marketCap":1548160192},{"date":"2020-10-23","current":-57.579104,"twenty":-223.145513,"median":-18.926233,"eighty":649.10488,"marketCap":1568224476},{"date":"2020-10-30","current":-52.525462,"twenty":-223.145513,"median":-18.979762,"eighty":649.10488,"marketCap":1430583484},{"date":"2020-11-06","current":-59.849141,"twenty":-223.145513,"median":-19.152472,"eighty":649.10488,"marketCap":1408369985},{"date":"2020-11-13","current":-61.878214,"twenty":-223.145513,"median":-19.216818,"eighty":649.10488,"marketCap":1456118141},{"date":"2020-11-20","current":-58.809028,"twenty":-223.145513,"median":-19.306102,"eighty":649.10488,"marketCap":1383894039},{"date":"2020-11-27","current":-60.343621,"twenty":-223.145513,"median":-19.411935,"eighty":649.10488,"marketCap":1420006090},{"date":"2020-12-04","current":-61.81001,"twenty":-223.145513,"median":-19.678226,"eighty":649.10488,"marketCap":1454513161},{"date":"2020-12-11","current":-62.321541,"twenty":-223.145513,"median":-19.76699,"eighty":649.10488,"marketCap":1466550511},{"date":"2020-12-18","current":-72.006531,"twenty":-223.145513,"median":-19.828442,"eighty":649.10488,"marketCap":1694457677},{"date":"2020-12-24","current":-75.178023,"twenty":-223.145513,"median":-19.951345,"eighty":649.10488,"marketCap":1769089249},{"date":"2020-12-31","current":-74.615339,"twenty":-223.145513,"median":-20.32132,"eighty":649.10488,"marketCap":1755848163},{"date":"2021-01-08","current":-79.06566,"twenty":-223.145513,"median":-20.427091,"eighty":649.10488,"marketCap":1860573111},{"date":"2021-01-15","current":-76.166984,"twenty":-223.145513,"median":-20.627956,"eighty":649.10488,"marketCap":1792361459},{"date":"2021-01-22","current":-79.543089,"twenty":-223.145513,"median":-20.814603,"eighty":649.10488,"marketCap":1871807971},{"date":"2021-01-29","current":-76.712617,"twenty":-223.145513,"median":-21.004841,"eighty":649.10488,"marketCap":1805201299},{"date":"2021-02-05","current":-82.625719,"twenty":-223.145513,"median":-21.125752,"eighty":649.10488,"marketCap":1667965385},{"date":"2021-02-12","current":-86.328944,"twenty":-223.145513,"median":-21.265484,"eighty":649.10488,"marketCap":1742722388},{"date":"2021-02-19","current":-82.685448,"twenty":-223.145513,"median":-21.492549,"eighty":649.10488,"marketCap":1669171143},{"date":"2021-02-26","current":-82.227523,"twenty":-223.145513,"median":-21.598052,"eighty":649.10488,"marketCap":1659926998},{"date":"2021-03-05","current":-80.117082,"twenty":-223.323098,"median":-21.772834,"eighty":649.309001,"marketCap":1617323544},{"date":"2021-03-12","current":-83.461931,"twenty":-223.323098,"median":-21.854907,"eighty":649.309001,"marketCap":1684845999},{"date":"2021-03-19","current":-80.435639,"twenty":-223.323098,"median":-21.959778,"eighty":649.309001,"marketCap":1623754254},{"date":"2021-03-26","current":-77.787635,"twenty":-223.145513,"median":-22.077677,"eighty":649.10488,"marketCap":1570298978},{"date":"2021-04-01","current":-74.442786,"twenty":-223.145513,"median":-22.365875,"eighty":649.10488,"marketCap":1502776524},{"date":"2021-04-09","current":-71.93415,"twenty":-223.323098,"median":-22.46194,"eighty":649.309001,"marketCap":1452134683},{"date":"2021-04-16","current":-77.608446,"twenty":-223.323098,"median":-22.539344,"eighty":649.309001,"marketCap":1566681704},{"date":"2021-04-23","current":-81.072753,"twenty":-223.323098,"median":-22.783943,"eighty":649.309001,"marketCap":1636615674},{"date":"2021-04-30","current":-80.276361,"twenty":-223.145513,"median":-22.907337,"eighty":649.10488,"marketCap":1620538899},{"date":"2021-05-07","current":-61.125515,"twenty":-223.145513,"median":-23.047069,"eighty":649.10488,"marketCap":1424346748},{"date":"2021-05-14","current":-62.685323,"twenty":-223.145513,"median":-23.118044,"eighty":649.10488,"marketCap":1460693394},{"date":"2021-05-21","current":-66.40818,"twenty":-223.145513,"median":-23.448954,"eighty":649.10488,"marketCap":1547443401},{"date":"2021-05-28","current":-67.545719,"twenty":-223.145513,"median":-23.542167,"eighty":649.10488,"marketCap":1573950347},{"date":"2021-06-04","current":-65.701526,"twenty":-223.145513,"median":-23.665911,"eighty":649.10488,"marketCap":1530976964},{"date":"2021-06-11","current":-68.131724,"twenty":-223.145513,"median":-23.842011,"eighty":649.10488,"marketCap":1587605441},{"date":"2021-06-18","current":-71.802875,"twenty":-223.145513,"median":-23.92517,"eighty":649.10488,"marketCap":1673150586},{"date":"2021-06-25","current":-75.887676,"twenty":-222.967928,"median":-24.312681,"eighty":648.900759,"marketCap":1768334621},{"date":"2021-07-02","current":-73.526419,"twenty":-222.967928,"median":-24.606789,"eighty":648.900759,"marketCap":1713312626},{"date":"2021-07-09","current":-74.112425,"twenty":-222.967928,"median":-44.751281,"eighty":648.900759,"marketCap":1726967720},{"date":"2021-07-16","current":-62.874913,"twenty":-222.967928,"median":-46.066945,"eighty":648.900759,"marketCap":1465111219},{"date":"2021-07-23","current":-67.631896,"twenty":-222.967928,"median":-46.851785,"eighty":648.900759,"marketCap":1575958449},{"date":"2021-07-30","current":-69.441618,"twenty":-222.967928,"median":-47.492643,"eighty":648.900759,"marketCap":1618128591},{"date":"2021-08-06","current":-116.556997,"twenty":-222.967928,"median":-48.109035,"eighty":648.900759,"marketCap":1564311458},{"date":"2021-08-13","current":-107.938662,"twenty":-222.967928,"median":-49.469834,"eighty":648.900759,"marketCap":1448644782},{"date":"2021-08-20","current":-109.829981,"twenty":-222.967928,"median":-51.159368,"eighty":648.900759,"marketCap":1474028176},{"date":"2021-08-27","current":-105.995219,"twenty":-222.967928,"median":-52.039983,"eighty":648.900759,"marketCap":1422561835},{"date":"2021-09-03","current":-108.212191,"twenty":-222.948196,"median":-53.089223,"eighty":648.898305,"marketCap":1452315813},{"date":"2021-09-10","current":-105.605751,"twenty":-222.948196,"median":-54.352435,"eighty":648.898305,"marketCap":1417334784},{"date":"2021-09-17","current":-109.620267,"twenty":-222.948196,"median":-55.22172,"eighty":648.898305,"marketCap":1471213610},{"date":"2021-09-24","current":-99.883567,"twenty":-222.948196,"median":-55.619529,"eighty":648.898305,"marketCap":1340537353},{"date":"2021-10-01","current":-102.201456,"twenty":-222.948196,"median":-56.577216,"eighty":648.898305,"marketCap":1371645743},{"date":"2021-10-08","current":-97.96826,"twenty":-222.928465,"median":-58.230986,"eighty":648.895851,"marketCap":1314832014},{"date":"2021-10-15","current":-101.354817,"twenty":-222.928465,"median":-59.228611,"eighty":648.895851,"marketCap":1360282997},{"date":"2021-10-22","current":-102.443353,"twenty":-222.928465,"median":-60.207213,"eighty":648.895851,"marketCap":1374892241},{"date":"2021-10-29","current":-106.071807,"twenty":-222.928465,"median":-61.050012,"eighty":648.895851,"marketCap":1423589723},{"date":"2021-11-05","current":-107.281292,"twenty":-222.928465,"median":-61.439537,"eighty":648.895851,"marketCap":1439822217},{"date":"2021-11-12","current":-55.251112,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":1102977952},{"date":"2021-11-19","current":-46.597813,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":930232140},{"date":"2021-11-26","current":-47.247826,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":943208351},{"date":"2021-12-03","current":-38.574214,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":770057033},{"date":"2021-12-10","current":-38.147643,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":761541394},{"date":"2021-12-17","current":-38.371085,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":766001967},{"date":"2021-12-23","current":-40.341437,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":805336107},{"date":"2021-12-31","current":-38.147643,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":761541394},{"date":"2022-01-07","current":-36.847617,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":735588972},{"date":"2022-01-14","current":-38.960159,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":777761658},{"date":"2022-01-21","current":-36.705426,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":732750426},{"date":"2022-01-28","current":-34.999142,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":698687871},{"date":"2022-02-04","current":-24.987669,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":721493944},{"date":"2022-02-11","current":-26.786556,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":773435015},{"date":"2022-02-18","current":-26.449265,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":763696064},{"date":"2022-02-25","current":-29.765963,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":859462415},{"date":"2022-03-04","current":-30.819998,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":889896636},{"date":"2022-03-11","current":-25.943327,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":749087638},{"date":"2022-03-18","current":-29.147595,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":841607671},{"date":"2022-03-25","current":-29.077326,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":839578723},{"date":"2022-04-01","current":-32.801585,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":947112973},{"date":"2022-04-08","current":-30.637299,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":884621371},{"date":"2022-04-14","current":-30.257846,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":873665051},{"date":"2022-04-22","current":-29.021111,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":837955565},{"date":"2022-04-29","current":-26.280619,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":758826589},{"date":"2022-05-06","current":-19.196392,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":624420233},{"date":"2022-05-13","current":-19.986315,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":650114860},{"date":"2022-05-20","current":-19.572546,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":636655770},{"date":"2022-05-27","current":-20.161854,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":655824777},{"date":"2022-06-03","current":-20.099161,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":653785521},{"date":"2022-06-10","current":-18.55693,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":603619820},{"date":"2022-06-17","current":-17.227853,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":560387590},{"date":"2022-06-24","current":-18.770084,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":610553291},{"date":"2022-07-01","current":-18.268545,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":594239242},{"date":"2022-07-08","current":-18.694853,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":608106183},{"date":"2022-07-15","current":-19.033392,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":619118167},{"date":"2022-07-22","current":-19.998854,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":650522711},{"date":"2022-07-29","current":-19.321776,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":628498745},{"date":"2022-08-05","current":-18.27617,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":674993785},{"date":"2022-08-12","current":-18.375557,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":678664446},{"date":"2022-08-19","current":-16.803903,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":620618538},{"date":"2022-08-26","current":-15.495084,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":572279932},{"date":"2022-09-02","current":-14.530107,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":536640452},{"date":"2022-09-09","current":-15.672551,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":578834319},{"date":"2022-09-16","current":-15.672551,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":578834319},{"date":"2022-09-23","current":-14.341549,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":529676415},{"date":"2022-09-30","current":-15.726213,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":580816217},{"date":"2022-10-07","current":-14.568872,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":538072166},{"date":"2022-10-14","current":-14.70503,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":543100878},{"date":"2022-10-21","current":-15.828331,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":584587751},{"date":"2022-10-28","current":-16.804128,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":620626852},{"date":"2022-11-04","current":-15.356608,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":598078472},{"date":"2022-11-11","current":-15.776012,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":614412548},{"date":"2022-11-18","current":-15.496409,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":603523164},{"date":"2022-11-25","current":-15.270577,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":594727893},{"date":"2022-12-02","current":-14.980221,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":583419686},{"date":"2022-12-09","current":-14.453279,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":562897386},{"date":"2022-12-16","current":-15.603949,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":607711389},{"date":"2022-12-23","current":-14.324231,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":557871516},{"date":"2022-12-30","current":-14.646849,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":570436190},{"date":"2023-01-06","current":-15.410378,"twenty":-221.981345,"median":-61.14502,"eighty":648.893398,"marketCap":600172585},{"date":"2023-01-13","current":-15.055498,"twenty":-220.996594,"median":-60.343621,"eighty":648.893398,"marketCap":586351444},{"date":"2023-01-20","current":-14.732881,"twenty":-218.210257,"median":-59.815039,"eighty":648.893398,"marketCap":573786770},{"date":"2023-01-27","current":-14.388755,"twenty":-216.298622,"median":-58.757875,"eighty":648.893398,"marketCap":560384451},{"date":"2023-02-03","current":-15.829781,"twenty":-213.098642,"median":-57.579104,"eighty":648.893398,"marketCap":616506661},{"date":"2023-02-10","current":-21.828798,"twenty":-209.864261,"median":-56.194141,"eighty":648.893398,"marketCap":826591078},{"date":"2023-02-17","current":-21.828798,"twenty":-206.639894,"median":-55.413615,"eighty":648.893398,"marketCap":826591078},{"date":"2023-02-24","current":-21.828798,"twenty":-204.396855,"median":-55.251112,"eighty":648.893398,"marketCap":826591078},{"date":"2023-03-03","current":-21.928523,"twenty":-200.181145,"median":-54.89758,"eighty":648.893398,"marketCap":830367383},{"date":"2023-03-10","current":-21.69583,"twenty":-195.294526,"median":-53.276878,"eighty":648.893398,"marketCap":821556006},{"date":"2023-03-17","current":-22.020055,"twenty":-191.11887,"median":-52.525462,"eighty":648.893398,"marketCap":833833428},{"date":"2023-03-24","current":-22.109205,"twenty":-188.575425,"median":-51.759312,"eighty":648.893398,"marketCap":837209272},{"date":"2023-03-31","current":-22.131493,"twenty":-184.820339,"median":-51.013718,"eighty":648.890944,"marketCap":838053233},{"date":"2023-04-06","current":-22.164924,"twenty":-177.300152,"median":-49.651896,"eighty":648.893398,"marketCap":839319174},{"date":"2023-04-14","current":-22.24293,"twenty":-171.241947,"median":-48.700677,"eighty":648.895851,"marketCap":842273038},{"date":"2023-04-21","current":-22.265218,"twenty":-159.435956,"median":-47.656498,"eighty":648.895851,"marketCap":843116999},{"date":"2023-04-26","current":-22.276361,"twenty":-150.263532,"median":-47.492643,"eighty":648.895851,"marketCap":843538979}],"updateTime":1757049158484},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSII\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2564390295","title":"AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer in Cardiovascular Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2564390295","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564390295?lang=en_us&edition=fundamental","pubTime":"2025-09-04 00:33","pubTimestamp":1756917233,"startTime":"0","endTime":"0","summary":"AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase III study titled A Phas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astrazenecas-phase-iii-study-on-azd0780-a-potential-game-changer-in-cardiovascular-treatment-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astrazenecas-phase-iii-study-on-azd0780-a-potential-game-changer-in-cardiovascular-treatment-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","III","BK4134","BK4082"],"gpt_icon":0},{"id":"2564398289","title":"Kiniksa Pharmaceuticals Highlights Cardiovascular Focus and Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398289?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:57","pubTimestamp":1756900636,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals ( ($KNSA) ) has shared an update. On September 3, 2025, Kiniksa Pharmaceuticals released an investor presentation detailing...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kiniksa-pharmaceuticals-highlights-cardiovascular-focus-and-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kiniksa-pharmaceuticals-highlights-cardiovascular-focus-and-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BK4082"],"gpt_icon":0},{"id":"2564389951","title":"Lexicon Pharmaceuticals’ Sotagliflozin Shows Promising Cardiovascular Benefits, Earning Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2564389951","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564389951?lang=en_us&edition=fundamental","pubTime":"2025-09-02 23:45","pubTimestamp":1756827909,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, retaining the price target of $4.00. Joseph Pantgin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/lexicon-pharmaceuticals-sotagliflozin-shows-promising-cardiovascular-benefits-earning-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/lexicon-pharmaceuticals-sotagliflozin-shows-promising-cardiovascular-benefits-earning-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXRX","CSII"],"gpt_icon":0},{"id":"2564807570","title":"Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2564807570","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564807570?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:30","pubTimestamp":1756816200,"startTime":"0","endTime":"0","summary":"Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of ageTHE WOODLANDS, Texas, Sept.  02, 2025  (GLOBE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3142691/0/en/Sotagliflozin-Provides-Consistent-Relative-Risk-Reduction-in-Heart-Failure-and-Major-Cardiovascular-Events-Across-All-Age-Ranges-Including-Greater-Than-75-in-Data-Presented-at-the-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCM","HF","BK4082","CSII","MACE","BK4585","CV","BK4183","BK4531","BK4007","BK4588","BK4157"],"gpt_icon":0},{"id":"2564843146","title":"Positive Outlook for Alnylam Pharma Amid Promising Cardiovascular Drug Developments and Strategic Partnerships","url":"https://stock-news.laohu8.com/highlight/detail?id=2564843146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564843146?lang=en_us&edition=fundamental","pubTime":"2025-09-01 22:45","pubTimestamp":1756737918,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on ALNY stock, giving a Buy rating on August 27. Myles Minter’s rating is ba...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-alnylam-pharma-amid-promising-cardiovascular-drug-developments-and-strategic-partnerships-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-alnylam-pharma-amid-promising-cardiovascular-drug-developments-and-strategic-partnerships-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BK4082"],"gpt_icon":0},{"id":"2563885041","title":"New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups","url":"https://stock-news.laohu8.com/highlight/detail?id=2563885041","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563885041?lang=en_us&edition=fundamental","pubTime":"2025-08-30 20:30","pubTimestamp":1756557000,"startTime":"0","endTime":"0","summary":"-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRID","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/30/3141868/18362/en/New-REDUCE-IT-Analyses-Presented-at-ESC-2025-Include-Data-Showing-VASCEPA-VAZKEPA-Icosapent-Ethyl-Therapy-Resulted-in-9-Fewer-Total-Hospitalizations-Reduces-Cardiovascular-Disease-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPE","BK4153","BK4604","AMRN","BK4082","TG","BK4090","BK4183","RRR","HR","BK4139","OR","BK4110","BK4157","BK4225","CSII","BK4161","ARR","BK4203","BK4150","MACE","TSS","BK4017"],"gpt_icon":1},{"id":"2563757883","title":"Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2563757883","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563757883?lang=en_us&edition=fundamental","pubTime":"2025-08-30 19:15","pubTimestamp":1756552500,"startTime":"0","endTime":"0","summary":"- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/30/3141857/0/en/Acoramidis-Demonstrates-Statistically-Significant-Reduction-in-Cardiovascular-Mortality-CVM-through-Month-42-of-the-ATTRibute-CM-Open-Label-Extension.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4207","CSII","BK4139","CVM","NAC","CM"],"gpt_icon":0},{"id":"2563793052","title":"AstraZeneca’s PRECEDE Study: Exploring COPD in Cardiovascular Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2563793052","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563793052?lang=en_us&edition=fundamental","pubTime":"2025-08-29 00:31","pubTimestamp":1756398682,"startTime":"0","endTime":"0","summary":"AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca has announced a new clinical study titled ‘The Prevalence, Di...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astrazenecas-precede-study-exploring-copd-in-cardiovascular-patients?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astrazenecas-precede-study-exploring-copd-in-cardiovascular-patients?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BK4082"],"gpt_icon":0},{"id":"2562922416","title":"Merck (MRK) Unveils New Cardiovascular Research Data at ESC 2025 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2562922416","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562922416?lang=en_us&edition=fundamental","pubTime":"2025-08-26 01:25","pubTimestamp":1756142727,"startTime":"0","endTime":"0","summary":"Merck (MRK) is set to present new clinical trial data at the European Society of Cardiology Congress 2025, emphasizing advancements in cardiovascular disease management. Over the last quarter, Merck's stock price increased by 13%, aligning closely with the overall market upswing driven by investor optimism regarding interest rate cuts. While Merck's developments, such as the clinical and regulatory progress with its drugs like WINREVAIR and KEYTRUDA, added weight to the company's movements,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/merck-mrk-unveils-new-cardiovascular-research-data-at-esc-20","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","LU0238689110.USD","LU1989772840.SGD","IE00BLSP4452.SGD","LU1116320901.HKD","LU1983299246.USD","LU2023250504.SGD","LU0058720904.USD","BK4007","LU1069347547.HKD","LU0208291251.USD","LU0266013472.USD","LU1023059063.AUD","LU1291159041.SGD","LU1162221912.USD","LU1571399168.USD","LU0265550946.USD","LU1974910355.USD","SG9999015358.SGD","LU1035773651.USD","LU1989771016.USD","MRK","LU1941712264.USD","SG9999014567.USD","LU0203345920.USD","BK4550","BK4516","LU0106261372.USD","LU0320765489.SGD","SG9999014542.SGD","LU1941712348.USD","LU2112291526.USD","IE0002141913.USD","LU1093756168.USD","IE00B4R5TH58.HKD","IE00BLSP4239.USD","SG9999013999.USD","SG9999015341.SGD","SG9999014575.USD","IE00BSNM7G36.USD","LU0211331839.USD","CSII","BK4533","LU2324357040.USD","LU1037948897.HKD","IE0009355771.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","LU1929549753.HKD"],"gpt_icon":0},{"id":"2562296226","title":"AstraZeneca’s AZD4144: A Promising Study in Cardiovascular and Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2562296226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562296226?lang=en_us&edition=fundamental","pubTime":"2025-08-26 00:32","pubTimestamp":1756139538,"startTime":"0","endTime":"0","summary":"AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase 1b study titled ‘A Phas...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astrazenecas-azd4144-a-promising-study-in-cardiovascular-and-kidney-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astrazenecas-azd4144-a-promising-study-in-cardiovascular-and-kidney-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BK4082"],"gpt_icon":0},{"id":"2559985102","title":"Tourmaline Bio: Strong Financial Position and Promising Cardiovascular Treatment Pipeline Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2559985102","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559985102?lang=en_us&edition=fundamental","pubTime":"2025-08-14 01:25","pubTimestamp":1755105936,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Tourmaline Bio today and set a price target of $58.00. Rami Katkhuda has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tourmaline-bio-strong-financial-position-and-promising-cardiovascular-treatment-pipeline-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tourmaline-bio-strong-financial-position-and-promising-cardiovascular-treatment-pipeline-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRML","CSII"],"gpt_icon":0},{"id":"2557560890","title":"Amgen’s Promising Cardiovascular Study: A Potential Game-Changer?","url":"https://stock-news.laohu8.com/highlight/detail?id=2557560890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557560890?lang=en_us&edition=fundamental","pubTime":"2025-08-08 00:15","pubTimestamp":1754583340,"startTime":"0","endTime":"0","summary":"Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Study Overview: Amgen Inc. is conducting a Phase 3 study titled A Phase 3 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-promising-cardiovascular-study-a-potential-game-changer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-promising-cardiovascular-study-a-potential-game-changer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","LU1057294990.SGD","LU2112291526.USD","CSII","LU1061106388.HKD","IE00BJT1NW94.SGD","LU1571399168.USD","LU0109394709.USD","BK4599","BK4581","BK4534","IE00BJJMRZ35.SGD","LU0868494617.USD","LU2089984988.USD","BK4139","BK4533","AMGN","IE0009355771.USD","IE00B4R5TH58.HKD","LU2468319806.SGD","LU1023059063.AUD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0122379950.USD","LU1983299246.USD","SG9999001440.SGD","LU0289739699.SGD","BK4082","LU2242652126.USD","BK4566","BK4585","LU0320765992.SGD","LU0058720904.USD","BK4588","LU2242646821.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2556881031","title":"AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer in Cardiovascular Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2556881031","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556881031?lang=en_us&edition=fundamental","pubTime":"2025-08-02 00:13","pubTimestamp":1754064816,"startTime":"0","endTime":"0","summary":"AstraZeneca (($AZN)), AstraZeneca plc (($GB:AZN)), AstraZeneca (($DE:ZEGA)), AstraZeneca plc US (($AZNCF)) announced an update on their ongoing cli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astrazenecas-phase-iii-study-on-azd0780-a-potential-game-changer-in-cardiovascular-health?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astrazenecas-phase-iii-study-on-azd0780-a-potential-game-changer-in-cardiovascular-health?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4134","BK4082","CSII","III"],"gpt_icon":0},{"id":"2553472792","title":"Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2553472792","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553472792?lang=en_us&edition=fundamental","pubTime":"2025-07-21 21:15","pubTimestamp":1753103700,"startTime":"0","endTime":"0","summary":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/21/3118790/0/en/Longeveron-Announces-Licensing-of-New-Cardiac-Selective-Induced-Pluripotent-Stem-Cell-Technology-for-Cardiovascular-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","CSII","BK4150","BK4575","LGVN","BK4139","MSC"],"gpt_icon":0},{"id":"2552459310","title":"Tempus AI (TEM) Gains FDA Clearance for New Cardiovascular Risk Detection Software","url":"https://stock-news.laohu8.com/highlight/detail?id=2552459310","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552459310?lang=en_us&edition=fundamental","pubTime":"2025-07-18 01:41","pubTimestamp":1752774109,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) has recently secured FDA clearance for its Tempus ECG-Low EF software, an innovative AI-driven product aiding cardiovascular assessments. This development aligns with TEM’s aim to enhance its ECG-AI technology leadership, potentially strengthening its market position. Alongside, the company's improved Q1 earnings report, with notable revenue growth from $146 million to $256 million, reflects its robust performance. Additionally, Tempus’s expansion into new strategic...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-tem-gains-fda-clearance-for-new-cardiovascular-ris","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4611","TEM.AU","BK4121","LU1861558580.USD","BK4082","TEM","CSII","LU1861559042.SGD","BK7095","BK4613"],"gpt_icon":1},{"id":"2552127212","title":"J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2552127212","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552127212?lang=en_us&edition=fundamental","pubTime":"2025-07-17 01:27","pubTimestamp":1752686820,"startTime":"0","endTime":"0","summary":"1327 ET - Johnson & Johnson expects medical technology sales to continue improving in the rest of the year, in part due to strong performance for its cardiovascular segment in its latest quarter, CEO Joaquin Duato says during a call with analysts. Operational sales of the segment were up 22%, driven by particularly strong growth for electrophysiology products and Abiomed, its subsidiary that manufactures cardiovascular medical implant devices, the company says. \"Cardiovascular has some of the largest unmet needs in health care, and is one of the fastest-growing spaces in medtech,\" Duato says.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSII","JNJ"],"gpt_icon":0},{"id":"2550620623","title":"Avricore Health Expands HealthTab™ Platform in NHS Cardiovascular Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2550620623","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550620623?lang=en_us&edition=fundamental","pubTime":"2025-07-11 01:10","pubTimestamp":1752167406,"startTime":"0","endTime":"0","summary":"An announcement from Avricore Health ( ($TSE:AVCR) ) is now available. Avricore Health has expanded its HealthTab™ platform into pharmacies in Nort...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/avricore-health-expands-healthtab-platform-in-nhs-cardiovascular-initiative?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/avricore-health-expands-healthtab-platform-in-nhs-cardiovascular-initiative?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","CSII"],"gpt_icon":0},{"id":"2550663605","title":"CRISPR Therapeutics (NasdaqGM:CRSP) Advances Cardiovascular Programs With Promising Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2550663605","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550663605?lang=en_us&edition=fundamental","pubTime":"2025-07-10 01:54","pubTimestamp":1752083695,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a substantial price movement, increasing 57% over the last quarter. This significant rise aligns with key developments, such as the company's inclusion in various Russell Indexes, enhancing its market visibility. Concurrently, CRISPR's progress in cardiovascular disease programs with CTX310™ and CTX320™ shows promising clinical trial results, likely fueling investor optimism. Amid a largely flat market, these elements likely contributed to the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-nasdaqgmcrsp-advances-cardiovascular-pro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRSP","LU1861558580.USD","CSII","BK4585","BK4588","BK4082","BK4556","BK4611","LU1861559042.SGD","BK4139"],"gpt_icon":0},{"id":"2546787945","title":"CRISPR Therapeutics Advances Phase 1 Trials for Cardiovascular Disease Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2546787945","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546787945?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:42","pubTimestamp":1750938165,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics  said Thursday that new phase 1 clinical data for its treatment CTX310 continues to demonstrate dose-dependent reductions in triglycerides and low-density lipoprotein, which are recognized risk factors for atherosclerotic heart disease.The data showed peak reduction of up to 82% in triglycerides and up to 86% in low-density lipoprotein, with a well-tolerated safety profile, the company said.CRISPR said it expects to present complete phase 1 data of CTX310, which targets the ANGPTL3 gene, at a medical meeting in H2.The company said it also expects an update for its phase 1 trial of CTX320 in H1 2026. The investigational treatment targets the LPA gene in patients with elevated lipoprotein, a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4539","BK4007","BK4556","BK4611","CSII","CRSP","BK4139","LU1861558580.USD","BK4082","LU1861559042.SGD","LENZ"],"gpt_icon":0},{"id":"2546242039","title":"Novo Nordisk’s ZEUS Study: A Potential Game Changer in Cardiovascular Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2546242039","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546242039?lang=en_us&edition=fundamental","pubTime":"2025-06-26 00:10","pubTimestamp":1750867848,"startTime":"0","endTime":"0","summary":"Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk is conducting a clinical study titled ‘ZEUS – Effects o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-zeus-study-a-potential-game-changer-in-cardiovascular-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-zeus-study-a-potential-game-changer-in-cardiovascular-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4006","LU0823414551.USD","LU1093756168.USD","LU0823414478.USD","LU1093756325.SGD","BK4133","CSII","LU2357125470.USD","NVO","BK4082","ZEUS","BK4588","BK4007","LU2249611893.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4585","NOVA","LU0154236417.USD","LU2506951792.HKD","LU2308191902.HKD","BK4532","BK4599","LU2294711713.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}